{"id":67168,"date":"2026-06-03T13:15:03","date_gmt":"2026-06-03T05:15:03","guid":{"rendered":"https:\/\/flcube.com\/?p=67168"},"modified":"2026-06-03T13:15:04","modified_gmt":"2026-06-03T05:15:04","slug":"systimmune-and-bristol-myers-squibbs-dual-targeted-adc-izalontamabbrengitecan-shows-significant-survival-benefit-in-two-phase-iii-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67168","title":{"rendered":"SystImmune and Bristol Myers Squibb’s Dual-Targeted ADC Izalontamabbrengitecan Shows Significant Survival Benefit in Two Phase III Trials"},"content":{"rendered":"\n

Izalontamabbrengitecan (iza-bren)<\/strong>, an EGFR and HER3-targeted antibody-drug conjugate (ADC)<\/strong> jointly developed by SystImmune<\/strong> (a subsidiary of Sichuan Biokin Pharmaceutical Co., Ltd.<\/strong>, (SHA: 688506<\/a>) and Bristol-Myers Squibb<\/strong> (BMS, NYSE: BMY<\/a>), has demonstrated statistically significant and clinically meaningful benefits<\/strong> in two pivotal Phase III clinical trials<\/strong> conducted in China.<\/p>\n\n\n\n

The investigational therapy showed robust overall survival (OS) and progression-free survival (PFS) advantages<\/strong> over standard chemotherapy in both metastatic breast cancer<\/strong> and esophageal cancer<\/strong> populations, positioning it as a potential new standard of care for these difficult-to-treat malignancies.<\/p>\n\n\n\n

Clinical Trial Portfolio Overview<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Developer Partnership<\/strong><\/td>SystImmune (Biokin Pharma subsidiary) + Bristol Myers Squibb<\/td><\/tr>
Molecule<\/strong><\/td>Izalontamabbrengitecan (iza-bren)<\/td><\/tr>
Targets<\/strong><\/td>Dual EGFR and HER3 inhibition<\/td><\/tr>
Therapy Class<\/strong><\/td>Antibody-Drug Conjugate (ADC)<\/td><\/tr>
Phase III Studies<\/strong><\/td>Three completed trials in China<\/td><\/tr>
Reported Results<\/strong><\/td>PANKU-Breast02 (BL-B01D1-307) and PANKU-Esophagus01 (BL-B01D1-305)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

PANKU-Breast02 Trial Results \u2013 Metastatic Breast Cancer<\/h2>\n\n\n\n
Endpoint<\/th>Iza-bren Arm<\/th>Chemotherapy Arm<\/th>Hazard Ratio\/Odds Ratio<\/th>p-value<\/th><\/tr><\/thead>
Median Overall Survival (OS)<\/strong><\/td>15.9 months<\/td>12.5 months<\/td>HR: 0.60 (95% CI: 0.42\u20130.85)<\/td>0.0019<\/td><\/tr>
Median PFS (BICR)<\/strong><\/td>8.5 months<\/td>3.1 months<\/td>HR: 0.29 (95% CI: 0.22\u20130.38)<\/td><0.0001<\/td><\/tr>
Objective Response Rate (ORR)<\/strong><\/td>51.7%<\/td>20.5%<\/td>OR: 4.3 (95% CI: 2.8\u20136.7)<\/td>\u2013<\/td><\/tr>
Follow-up Duration<\/strong><\/td>Median 11 months<\/td>\u2013<\/td>\u2013<\/td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

PANKU-Esophagus01 Trial Results \u2013 Esophageal Cancer<\/h2>\n\n\n\n
Endpoint<\/th>Iza-bren Arm<\/th>Chemotherapy Arm<\/th>Hazard Ratio<\/th>p-value<\/th><\/tr><\/thead>
Median Overall Survival (OS)<\/strong><\/td>9.8 months<\/td>7.2 months<\/td>HR: 0.64 (95% CI: 0.49\u20130.83)<\/td>0.0004<\/td><\/tr>
Median PFS (BICR)<\/strong><\/td>4.2 months<\/td>2.0 months<\/td>HR: 0.50 (95% CI: 0.40\u20130.63)<\/td><0.0001<\/td><\/tr>
Objective Response Rate (ORR)<\/strong><\/td>35.3%<\/td>13.1%<\/td>\u2013<\/td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Partnership Implications<\/h2>\n\n\n\n